louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03747588: The Comparision of Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer
Official title: The Effect and Safety of Comparision Between Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer : A Randomized Prospective Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pancreatic Carcinoma
Surgery
Keywords: minimally-invasive pancreaticoduodenectomy
open pancreaticoduodenectomy
pancreatic cancer
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2018-11-20
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Minimally invasive pancreaticoduodenectomy remains one of the most challenging abdominal procedures. Safety and feasibility remain controversial when comparing minimally-invasive with open pancreaticoduodenectomy, especially for malignant tumors.The aim of this study was to compare minimally invasive and open pancreatoduodenectomy for short-term outcomes and long-term follow-up in a randomized trial.

Detailed description: This study is to compare the efficiency and safety between minimally invasive (including laparoscopic and robotic) and open pancreaticoduodenectomy for pancreatic cancer. We design a prospective randomized study. Patients with malignant pancreatic tumor who underwent pancreatoduodenectomy are recruited to the study. After obtaining informed consent, eligible patients are randomly allocated to minimally-invasive or open group before the operation day. The outcomes evaluated were hospital stay, and blood loss, radicality of surgery, duration of operation and complication rate as well as disease free survival and overall survival.

Eligibility criteria: Inclusion Criteria:

* Age: \>18yr, \<75yr
* Patients with pancreatic cancer or non-pancreatic cancers (biliary duct cancer or ampullary cancer) who underwent pancreatoduodenectomy
* Preoperative imaging assessment is resectable or borderline resectable

Exclusion Criteria:

* Benign tumors of the head of pancreas
* Enhanced CT diagnosis revealed that the excess of SMV was more than 180 degrees, or distant metastasis.
* conversion to laparotomy because of intraoperative difficulty

Primary outcomes:
measure: Overall complications
timeFrame: Up to postoperative 30 days
measure: Pancreatic fistula
timeFrame: Up to postoperative 30 days
measure: Intra-abdominal bleeding
timeFrame: Up to postoperative 30 days
measure: Intra-abdominal infection
timeFrame: Up to postoperative 30 days
Secondary outcomes:
measure: Length of hospital stay (day)
timeFrame: Up to postoperative 2 weeks
Other outcomes:
measure: progression-free survival
timeFrame: Up to postoperative 5 years
Locations:
city: Beijing
country: China
facility: Chinese Academy of Medical Sciences & Peking Union Medical College Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT01337388: An Observational Study of RoActemra/Actemra (Tocilizumab) in Smoking Versus Non-Smoking Patients With Rheumatoid Arthritis
Official title: An Observational Study of the Efficacy of RoActemra in Smoking vs Non-smoking Patients With Rheumatoid Arthritis.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatoid Arthritis
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2011-04-18
Enrollment: 197
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Rheumatoid arthritis patients on treatment with RoActemra/Actemra

Brief summary: This observational study will assess the efficacy and safety of RoActemra/Actemra (Tocilizumab) in smoking versus non-smoking patients with rheumatoid arthritis. Data from patients treated in routine clinical practice with intravenous RoActemra/Actemra will be collected for 12 months each.


Eligibility criteria: Inclusion Criteria:

* Adult patients, \> 18 years of age
* Rheumatoid arthritis, defined as fulfilling at least 4 of 7 American College of Rheumatology (ACR) criteria
* Treatment with RoActemra/Actemra

Exclusion Criteria:

* Participation in interventional clinical studies

Primary outcomes:
measure: Change in disease activity score (DAS 28)
timeFrame: 12 months
measure: Treatment patterns (frequency/dosage) and demographics of patients treated with RoActemra/Actemra in routine clinical practice
timeFrame: 36 months
Secondary outcomes:
measure: Safety: Incidence of adverse events
timeFrame: 36 months
measure: Quality of life: Health assessment questionnaire Disease Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy- Fatigue (FACIT-Fatigue) questionnaire
timeFrame: 12 months
measure: Rate of patients achieving remission (DAS <2.6)
timeFrame: 36 months
measure: Change in blood lipids
timeFrame: 12 months
measure: Clinical response (DAS 28/blood chemistry/QoL) with or without methotrexate
timeFrame: 36 months
Other outcomes:
Locations:
city: Bergen
country: Norway
city: Drammen
country: Norway
city: Gjettum
country: Norway
city: Kristiansand
country: Norway
city: Levanger
country: Norway
city: Lillehammer
country: Norway
city: Skien
country: Norway
city: Trondheim
country: Norway
city: Ålesund
country: Norway
city: Eskilstuna
country: Sweden
city: Falun
country: Sweden
city: Farsta
country: Sweden
city: Göteborg
country: Sweden
city: Kalmar
country: Sweden
city: Karlstad
country: Sweden
city: Kristianstad
country: Sweden
city: Linkoeping
country: Sweden
city: Lulea
country: Sweden
city: Malmo
country: Sweden
city: Oerebro
country: Sweden
city: Oskarstroem
country: Sweden
city: Simrishamn
country: Sweden
city: Skoevde
country: Sweden
city: Stockholm
country: Sweden
city: Stockholm
country: Sweden
city: Uddevalla
country: Sweden
city: Uppsala
country: Sweden
city: Västerås
country: Sweden
city: Östersund
country: Sweden
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT06885788: Uterine Round Ligament Preservation Vs Resection in Laparoscopic Inguinal Hernia Repair in Women：A Multicenter,Stratified Randomized Controlled Trial
Official title: Comparative Study on the Effect of Uterine Round Ligament Preservation Vs Resection in Laparoscopic Inguinal Hernia Repair in Women： a Multicenter,Stratified Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Inguinal Hernia
Laparoscopic Surgery
Randomized Controlled Trial
Lead sponsor: Nanchong Central Hospital
Sponsor class: OTHER_GOV
First posted: 2025-03-20
Enrollment: 466
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study aims to compare the clinical effects of uterine round ligament preservation versus resection in laparoscopic inguinal hernia repair in women.The primary outcomes included Time required for patient surgery.The secondary outcomes included Inguinal hernia recurrence,quality of life assessment,Indicators of postoperative recovery,, et al.


Eligibility criteria: Inclusion Criteria:

* ►Age : Female patients over 18 years of age without a childbearing requirement

  * Diagnosis and basis : Female patients diagnosed with Unilateral inguinal hernia.
  * agreed to participate in this study and signed the informed consent form.

Exclusion Criteria:

* ►Combined with severe heart, liver, kidney and other diseases.

  * pregnant or lactating women.
  * those with surgical contraindications.

Primary outcomes:
measure: Time required for patient surgery
timeFrame: 20-120minutes
Secondary outcomes:
measure: Inguinal hernia recurrence
timeFrame: 1 month, 3 months, 6 months,1year,2years,3years,6years
measure: Quality of life assessment
timeFrame: 3 months,6months,1year,2years,3years,6years
Other outcomes:
Locations:
city: Nanchong
country: China
facility: Nanchong Central Hospital
state: Sichuan
Study officials:
References:
Clinical trial NCT02477488: Optimal Administration of Allopurinol in Dialysis Patients
Official title: Optimal Administration of Allopurinol in Dialysis Patients : A Chronotherapy Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Gout
Renal Insufficiency
Keywords: Allopurinol
Renal Dialysis
Lead sponsor: Maisonneuve-Rosemont Hospital
Sponsor class: OTHER
First posted: 2015-06-22
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Gout has a strong association with the metabolic syndrome, and it is often seen in patients with renal insufficiency. Allopurinol is a medication intended to lower uric acid and therefore prevents gout attacks. Its metabolism is mainly renal, and some evidence shows that it is also dialyzable. The hypothesis is that allopurinol would be more efficacious to lower uric acid if it was given after dialysis only. The investigators will then switch administration of allopurinol to bedtime for dialysis patients currently taking that medication.

Detailed description: Gout has a strong association with the metabolic syndrome, and it is often seen in patients with renal insufficiency. A study has shown an incidence of fifteen percent of gout in the first five years spent in dialysis and it was associated with an increased mortality. Allopurinol is a medication intended to lower uric acid and therefore prevents gout attacks. Its metabolism is mainly renal, and some studies from the early 1960s demonstrated that it is also dialyzable. At the moment, we do not have strong evidence of the optimal dosage of allopurinol with modern techniques of dialysis. The hypothesis is that allopurinol would be more efficacious to lower uric acid if it was given after dialysis only. The investigators will then switch administration of allopurinol to bedtime for dialysis patients currently taking that medication. Dosage of uric acid will be performed to assess the efficacy of the intervention.

Eligibility criteria: Inclusion Criteria:

* Subjects who receive chronic treatments of hemodialysis at Maisonneuve-Rosemont Hospital
* Subjects who take allopurinol for at least a month

Exclusion Criteria:

* Subjects who have had an acute gout attack in the past month
* Subjects with tumor lysis syndrome
* Sujects who have a history of hypersensitivity reaction to allopurinol
* Subjects with hepatic insufficiency
* Women who are pregnant or planning to become pregnant in the next three months

Primary outcomes:
measure: Change in uric acid levels from baseline
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Maisonneuve-Rosemont Hospital
state: Quebec
Study officials:
affiliation: Maisonneuve-Rosemont Hospital
name: Michel Vallée, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cohen SD, Kimmel PL, Neff R, Agodoa L, Abbott KC. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol. 2008 Nov;19(11):2204-10. doi: 10.1681/ASN.2007111256. Epub 2008 May 28.
Clinical trial NCT05167188: Evaluation of GvHD Damage on Medullary Mesenchymal Stem Cells
Official title: Prospective Multicenter Study for the Evaluation of GvHD Damage on Medullary Mesenchymal Stem Cells - GvHD Damage on MSCs
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Graft Vs Host Disease
Lead sponsor: Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Sponsor class: OTHER
First posted: 2021-12-22
Enrollment: 25
Sex: ALL
Minimum age (years): 6
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients (children and adults) developing acute or chronic GvHD after HSCT

Brief summary: Spontaneous, multicenter, prospective, non-pharmacological study. At the diagnosis of acute or chronic GvHD after HSCT, bone marrow cells will be analysed for MSC content and properties. Bone marrow aspirate will be performed according to usual clinical practise


Eligibility criteria: Inclusion Criteria:

* Patients (children and adults) developing acute or chronic GvHD after HSCT.
* Age 6 months- month-99 years,
* Landsky-Karnofsky\> 70%,
* Acute or chronic GvHD needing further immunosuppressive treatment.

Exclusion Criteria:

* Anything not included in the inclusion criteria.

Primary outcomes:
measure: Evaluation of damage generated by acute or chronic GvHD on the MSCs after HSCT
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Torino
country: Italy
facility: AOU Città della Salute e della Scienza di Torino
Study officials:
References:
Clinical trial NCT04300088: A Prospective Study of the Relevance of the HLA-G Immune Checkpoint in Cancer Immunotherapy
Official title: A Prospective Study of the Relevance of the HLA-G Immune Checkpoint in Cancer Immunotherapy
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Solid Tumor
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2020-03-09
Enrollment: 281
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with advanced solid cancer treated with anti-PD(L)1 immunotherapy with or without anti-CTLA4 immunotherapy.

Brief summary: Therapeutic targeting of immune checkpoints PD-1/PD-L1 and/or CTLA-4 is efficient in several solid cancer subtypes, however only some patients do experience clinical benefit from these treatments. One explanation could be that multiple redundant checkpoints are present within the tumor, simultaneously keeping in check the patient's immune response. The immune checkpoint HLA-G is neo-expressed in over 50% of cases in some cancer subtypes and associated with more dismal prognosis. The immunosuppressive effects of HLA-G may result in resistance to current immunotherapy drugs.

The GEIA study explores the impact of HLA-G tumor expression on the efficacy of cancer immunotherapy in solid cancer patients.


Eligibility criteria: Inclusion Criteria:

* Age 18 or older
* Social insurance
* Ability to provide signed consent
* Histologically proven solid cancer (non-small cell lung cancer, urothelial carcinoma, renal cell carcinoma, other)
* Advanced and/or metastatic disease not accessible to local treatment
* At least one target lesion according to iRECIST
* Available fixed tumor sample for immunohistochemistry studies
* Treatment with anti-PD(L)1 immunotherapy with or without anti-CTLA4 immunotherapy

Exclusion Criteria:

* Women pregnant or breastfeeding
* Inability to consent to this research
* Previous cancer immunotherapy (except BCG instillations for non-muscle infiltrative bladder cancer)
* Patients chronically infected with HIV, HBV or HCV

Primary outcomes:
measure: Objective tumor response rate
timeFrame: at 6 months
Secondary outcomes:
measure: Progression free-survival
timeFrame: at 6 months
measure: Progression free-survival
timeFrame: at 1 year
measure: Progression free-survival
timeFrame: at 2 years
measure: Overall survival
timeFrame: at 6 months
measure: Overall survival
timeFrame: at 1 year
measure: Overall survival
timeFrame: at 2 years
measure: Specific disease survival
timeFrame: at 6 months
measure: Specific disease survival
timeFrame: at 1 year
measure: Specific disease survival
timeFrame: at 2 years
measure: Incidence of adverse events
timeFrame: at 2 years
measure: Soluble HLA-G levels counts
timeFrame: Up to 24 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06300788: Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease
Official title: Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease - PPi-DIA
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pyrophosphate, Fetuin A, IL1, IL6, TNFalpha, Control
Keywords: Pyrophosphate
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2024-03-08
Enrollment: 60
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The investigator aim to identify the role of inorganic pyrophosphate and other anti-calcifying molecules in vascular disease in children with chronic kidney disease, with a view to developing therapeutic approaches aimed at limiting the onset of vasculopathy.

Detailed description: The study of pro- and anti-calcifying molecules in children with chronic kidney disease will be carried out using dosages made on serum in comparison with the dosage of these same molecules in control children matched according to age and sex. without chronic kidney disease. An evaluation of vascular function by clinical (auscultation, palpation) and ultrasound techniques (measurement of intima-media thickness and measurement of pulse wave velocity) will also be carried out in children with chronic kidney disease and compared to norms of children without chronic kidney disease. These evaluations aim to improve understanding of the pathophysiology of vascular calcification and thus open up therapeutic perspectives in these children.

Eligibility criteria: Inclusion Criteria:

All groups :

* Minor patients (\<18 years)
* Patients of both sexes
* Informed patients and parents who have signed the informed consent form
* Patients affiliated to social security

Control group :

- Patients with no particular pathology undergoing surgery and receiving a preoperative check-up

CKD groups :

* Patients on dialysis for more than 3 months, regardless of technique
* Kidney transplant patients
* Patients with CKD, whatever the cause

Exclusion Criteria:

* Progressive cancer or kidney disease
* Treatments that may modify PPi concentration (e.g. bisphosphonates)

Primary outcomes:
measure: Plasma pyrophosphate concentration [PPi]pl in children with CKD
timeFrame: 18 months
Secondary outcomes:
measure: Plasma pyrophosphate [PPi]pl concentration in children with renal transplantation
timeFrame: 18 months
measure: Markers of phosphocalcic metabolism
timeFrame: 18 months
measure: Urinary PPi concentration
timeFrame: 18 months
measure: Markers of vascular damage in CKD
timeFrame: 18 months
Other outcomes:
Locations:
city: Nice
country: France
facility: CHU Nice - Hôpital de l'Archet 2
state: Alpes-Maritimes
Study officials:
References:
Clinical trial NCT01983488: Clinical Outcome in Uveitis
Official title: Clinical Outcome and Causes of Visual Loss in Uveitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Uveitis
Keywords: Uveitis
Vision Loss
Lead sponsor: Moorfields Eye Hospital NHS Foundation Trust
Sponsor class: OTHER
First posted: 2013-11-14
Enrollment: 231
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient data will be gathered from the uveitis clinic at Moorfields Eye Hospital.

Brief summary: This study is aimed at investigating the long term clinical outcome of patients with uveitis.

Detailed description: Patients will be included if they are treated for uveitis and have had repeat follow-up. Data will be gathered from the entire length of the patients follow-up.

The main outcome measures will be:

Change from baseline of Best corrected visual acuity (BCVA)at 10 years Causes of vision loss (≤6/15, VL) and severe vision loss (≤6/60, SVL) at 10 years Number of clinical visits at 10 years.

Eligibility criteria: Inclusion Criteria:

* Clinical Diagnosis of Uveitis.

Exclusion Criteria:

* No follow-up data.

Primary outcomes:
measure: Best Corrected Visual Acuity
timeFrame: up to 10 years
Secondary outcomes:
measure: Causes of visual loss
timeFrame: First follow-up, years 1,2,5,10, Final follow-up
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Moorfields Eye Hospital
Study officials:
affiliation: Moorfields Eye Hospital NHS Foundation Trust
name: Sue Lightman, PhD,FRCOphth
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996 Apr;80(4):332-6. doi: 10.1136/bjo.80.4.332.
citation: Bodaghi B, Cassoux N, Wechsler B, Hannouche D, Fardeau C, Papo T, Huong DL, Piette JC, LeHoang P. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore). 2001 Jul;80(4):263-70. doi: 10.1097/00005792-200107000-00005. No abstract available.
Clinical trial NCT01954888: Impact of the Ultrasound-guided Approach on the Efficiency and Safety of the Stellate Ganglion Block in Chronic Pain
Official title: Impact of the Ultrasound-guided Approach on the Efficiency and Safety of the Stellate Ganglion Block in Chronic Pain
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Complex Regional Pain Syndromes
Lead sponsor: Maisonneuve-Rosemont Hospital
Sponsor class: OTHER
First posted: 2013-10-07
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The first purpose of this study is to compare the effectiveness of the stellate ganglion block realized with two different approaches (blind and ultrasound-guided) in patients with a diagnosis of complex regional pain syndrome.

The second purpose of this study is to determine the safest approach and to compare the safety profiles of the two approaches.

Detailed description: To evaluate whether the ultrasound guided approach is more effective than the blind technique in producing a greater than 1.5 degree Celsius rise in ipsilateral arm temperature after a stellate ganglion block.

Blocks will both be performed with 10 mL of xylocaine/bupivacaine. Secondary outcomes will be the impact of the approach (blind vs ultrasound) on pain reduction, horner syndrome, side effects (hoarseness, dysphagia, pharyngeal discomfort) and complications (blood aspiration, intravascular injection).

Eligibility criteria: Inclusion Criteria:

* Patients aged 18 to 80 years
* Patients with a new or known diagnosis of complex regional pain syndrome (according to the criteria of Budapest) at the upper extremity

Exclusion Criteria:

* Refusal of a patient
* Coagulopathy
* Systemic infection or local infection at the needle injection site
* Major deformation at the level of the neck (radiotherapy, surgery, etc. )
* Concomitant chronic pain syndrome
* Post-pneumonectomy on the controlateral side
* Severe hepatic impairment or severe renal impairment (Clcr under 30 ml/min)
* Known allergy to local anesthetics of amide type
* Inability to understand a numeric pain scale

Primary outcomes:
measure: proportion of patients reaching >1.5 °C rise in ipsilateral arm temperature
timeFrame: thirty minutes after block
Secondary outcomes:
measure: Complications
timeFrame: Time of the block to one week after the block
Other outcomes:
measure: Severity of pain
timeFrame: Immediately and each day after the block until one week after the block
Locations:
city: Montreal
country: Canada
facility: Maisonneuve-Rosemont Hospital
state: Quebec
Study officials:
affiliation: Maisonneuve-Rosemont Hospital
name: Veronique Brulotte, MD, MSC, FRCPC
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bhatia A, Flamer D, Peng PW. Evaluation of sonoanatomy relevant to performing stellate ganglion blocks using anterior and lateral simulated approaches: an observational study. Can J Anaesth. 2012 Nov;59(11):1040-7. doi: 10.1007/s12630-012-9779-4. Epub 2012 Sep 6.